STE Form 4: CEO reports 51,096 shares owned; 33,054 restricted
Rhea-AI Filing Summary
Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on 10/06/2025 at a price of $241.82 per share, leaving beneficial ownership of 51,096 shares. The filing indicates 33,054 of those shares are restricted with scheduled lapses: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), and 06/05/2028 (5,937). The form is filed individually and indicates the transaction was reported under a Rule 10b5-1 plan.
Positive
- Transaction reported under a Rule 10b5-1 plan, indicating a pre-established trading arrangement
- Form filed promptly and includes a clear vesting schedule for restricted shares
Negative
- Insider sold 159 shares, reducing direct holdings (immaterial in size)
- 33,054 shares are restricted, which will vest in tranches through 06/05/2028, potentially increasing float over time
Insights
Small, routine sale by an insider under a 10b5-1 plan; majority of holdings remain restricted.
The reported sale of 159 shares at $241.82 is de minimis relative to total holdings of 51,096 shares, and the filing marks the transaction as pursuant to a Rule 10b5-1 plan, which provides a pre-established trading schedule.
The holding profile shows 33,054 restricted shares with specific vesting dates through 06/05/2028, indicating staged equity retention that ties a material portion of insider equity to future time-based milestones.
Transaction size is immaterial but disclosure and vesting schedule are investor-relevant.
The disposal code and reported price confirm an open-market sale on 10/06/2025; because only 159 shares were sold, there is no immediate material change to ownership percentage.
Investors monitoring insider alignment should note the detailed vesting timetable with multiple tranches maturing between 06/01/2026 and 06/05/2028, which could incrementally increase freely tradable shares over that horizon.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 159 | $241.82 | $38K |
Footnotes (1)
- F1. As of October 6, 2025, 33,054 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 4,308 on June 1, 2026; 5,937 on June 3, 2026; 2,369 on June 2, 2026; 4,283 on June 4, 2026; 5,937 on June 3, 2027; 4,283 on June 4, 2027; and 5,937 on June 5, 2028.
FAQ
What did the STERIS (STE) Form 4 filed by Daniel A. Carestio disclose?
Was the sale by the STE insider executed under a 10b5-1 plan?
Does the Form 4 indicate a material change in ownership for STE?
Who signed the Form 4 for the reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.